OA11823A - S-nitrosothiols as agents for the treatment of circulatory dysfunctions. - Google Patents

S-nitrosothiols as agents for the treatment of circulatory dysfunctions. Download PDF

Info

Publication number: OA11823A
Authority: OA; OAPI
Prior art keywords: rest; amino; glycine; compound; acetyl
Prior art date: 1999-01-27

Application number

OA1200100195A

Other languages

English (en)

Inventor

Jose Repolles Moliner

Perez-Rasilla Eduardo Salas

Francisco Pubill Coy

Juan Antonio Cerda Riudavets

Cristina Negrie Rofes

Lydia Cabeza Llorente

Alicia Ferrer Siso

Nuria Trias Adroher

Marcel Li Carbo Banus

Jesus Murat Moreno

Pedro Michelenallaguno

Original Assignee

Lacer Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-27

Filing date

2000-01-19

Publication date

2005-08-16

2000-01-19 Application filed by Lacer Sa filed Critical Lacer Sa

2005-08-16 Publication of OA11823A publication Critical patent/OA11823A/en

Links

230000005794 circulatory dysfunction Effects 0.000 title claims 2
150000001875 compounds Chemical class 0.000 claims abstract description 39
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims abstract description 17
239000004471 Glycine Substances 0.000 claims abstract description 15
235000001014 amino acid Nutrition 0.000 claims abstract description 15
239000004220 glutamic acid Substances 0.000 claims abstract description 8
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims abstract description 7
235000013922 glutamic acid Nutrition 0.000 claims abstract description 7
125000002252 acyl group Chemical group 0.000 claims abstract description 6
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 claims abstract description 6
125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract description 6
LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical class OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 claims abstract description 5
125000000217 alkyl group Chemical group 0.000 claims abstract description 5
230000004064 dysfunction Effects 0.000 claims abstract description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 4
108010024636 Glutathione Proteins 0.000 claims abstract description 3
125000001931 aliphatic group Chemical group 0.000 claims abstract description 3
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 3
229960003180 glutathione Drugs 0.000 claims abstract description 3
229910052739 hydrogen Inorganic materials 0.000 claims abstract description 3
239000001257 hydrogen Substances 0.000 claims abstract description 3
239000001301 oxygen Substances 0.000 claims abstract description 3
229910052760 oxygen Inorganic materials 0.000 claims abstract description 3
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 3
229910052717 sulfur Inorganic materials 0.000 claims abstract description 3
239000011593 sulfur Substances 0.000 claims abstract description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 56
229940024606 amino acid Drugs 0.000 claims description 15
-1 S-nitrosomercapto Chemical class 0.000 claims description 11
229960002989 glutamic acid Drugs 0.000 claims description 6
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 5
229960001639 penicillamine Drugs 0.000 claims description 4
238000004519 manufacturing process Methods 0.000 claims description 3
125000004429 atom Chemical group 0.000 claims description 2
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 2
125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 2
SGPGESCZOCHFCL-UHFFFAOYSA-N Tilisolol hydrochloride Chemical compound [Cl-].C1=CC=C2C(=O)N(C)C=C(OCC(O)C[NH2+]C(C)(C)C)C2=C1 SGPGESCZOCHFCL-UHFFFAOYSA-N 0.000 claims 1
229950009215 phenylbutanoic acid Drugs 0.000 claims 1
150000003839 salts Chemical class 0.000 claims 1
230000002776 aggregation Effects 0.000 abstract description 11
238000004220 aggregation Methods 0.000 abstract description 11
230000000304 vasodilatating effect Effects 0.000 abstract description 9
230000002526 effect on cardiovascular system Effects 0.000 abstract description 4
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
239000000047 product Substances 0.000 description 32
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 24
238000004128 high performance liquid chromatography Methods 0.000 description 24
238000000034 method Methods 0.000 description 23
239000000243 solution Substances 0.000 description 19
229910001868 water Inorganic materials 0.000 description 19
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 18
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 17
239000000203 mixture Substances 0.000 description 17
HYHSBSXUHZOYLX-WDSKDSINSA-N S-nitrosoglutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CSN=O)C(=O)NCC(O)=O HYHSBSXUHZOYLX-WDSKDSINSA-N 0.000 description 16
KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
239000007787 solid Substances 0.000 description 14
239000002904 solvent Substances 0.000 description 14
238000012360 testing method Methods 0.000 description 14
238000005481 NMR spectroscopy Methods 0.000 description 13
230000005764 inhibitory process Effects 0.000 description 13
230000002829 reductive effect Effects 0.000 description 13
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
239000000543 intermediate Substances 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 11
238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 10
MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
230000000694 effects Effects 0.000 description 8
238000005859 coupling reaction Methods 0.000 description 7
235000013350 formula milk Nutrition 0.000 description 7
239000012071 phase Substances 0.000 description 7
108090000765 processed proteins & peptides Proteins 0.000 description 7
239000011347 resin Substances 0.000 description 7
229920005989 resin Polymers 0.000 description 7
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 6
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 6
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
229940125898 compound 5 Drugs 0.000 description 6
239000011521 glass Substances 0.000 description 6
238000000338 in vitro Methods 0.000 description 6
230000002401 inhibitory effect Effects 0.000 description 6
239000013067 intermediate product Substances 0.000 description 6
238000010168 coupling process Methods 0.000 description 5
YMWUJEATGCHHMB-UHFFFAOYSA-N dichloromethane Natural products ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 5
DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Substances OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
238000002211 ultraviolet spectrum Methods 0.000 description 5
IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 4
238000004458 analytical method Methods 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
230000008878 coupling Effects 0.000 description 4
229910052805 deuterium Inorganic materials 0.000 description 4
210000003918 fraction a Anatomy 0.000 description 4
235000011167 hydrochloric acid Nutrition 0.000 description 4
229960000443 hydrochloric acid Drugs 0.000 description 4
FEMOMIGRRWSMCU-UHFFFAOYSA-N ninhydrin Chemical compound C1=CC=C2C(=O)C(O)(O)C(=O)C2=C1 FEMOMIGRRWSMCU-UHFFFAOYSA-N 0.000 description 4
230000003389 potentiating effect Effects 0.000 description 4
238000001228 spectrum Methods 0.000 description 4
238000005406 washing Methods 0.000 description 4
JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 3
SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
206010047141 Vasodilatation Diseases 0.000 description 3
WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 3
229910052786 argon Inorganic materials 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
210000002196 fr. b Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
238000004949 mass spectrometry Methods 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
230000009935 nitrosation Effects 0.000 description 3
238000007034 nitrosation reaction Methods 0.000 description 3
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000011160 research Methods 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
239000000523 sample Substances 0.000 description 3
230000002792 vascular Effects 0.000 description 3
230000024883 vasodilation Effects 0.000 description 3
AMSWGYNUINZOII-UHFFFAOYSA-N 2-acetamido-3-benzyl-4-phenyl-3-sulfanylbutanoic acid Chemical compound C=1C=CC=CC=1CC(S)(C(C(O)=O)NC(=O)C)CC1=CC=CC=C1 AMSWGYNUINZOII-UHFFFAOYSA-N 0.000 description 2
WBQMAVMLZZSPQW-UHFFFAOYSA-N 2-amino-3-benzyl-4-phenyl-3-sulfanylbutanoic acid Chemical compound C=1C=CC=CC=1CC(S)(C(C(O)=O)N)CC1=CC=CC=C1 WBQMAVMLZZSPQW-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
241000819038 Chichester Species 0.000 description 2
YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 description 2
QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
ZIIQCSMRQKCOCT-YFKPBYRVSA-N S-nitroso-N-acetyl-D-penicillamine Chemical compound CC(=O)N[C@@H](C(O)=O)C(C)(C)SN=O ZIIQCSMRQKCOCT-YFKPBYRVSA-N 0.000 description 2
DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 2
239000002253 acid Substances 0.000 description 2
230000002785 anti-thrombosis Effects 0.000 description 2
238000003556 assay Methods 0.000 description 2
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
238000007796 conventional method Methods 0.000 description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
239000003480 eluent Substances 0.000 description 2
238000000605 extraction Methods 0.000 description 2
SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 2
238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 2
IWDCLRJOBJJRNH-UHFFFAOYSA-N p-cresol Chemical compound CC1=CC=C(O)C=C1 IWDCLRJOBJJRNH-UHFFFAOYSA-N 0.000 description 2
238000010647 peptide synthesis reaction Methods 0.000 description 2
235000011007 phosphoric acid Nutrition 0.000 description 2
229940093956 potassium carbonate Drugs 0.000 description 2
229910000027 potassium carbonate Inorganic materials 0.000 description 2
235000011181 potassium carbonates Nutrition 0.000 description 2
230000004224 protection Effects 0.000 description 2
239000011734 sodium Substances 0.000 description 2
LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
239000007790 solid phase Substances 0.000 description 2
208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
DWPVVZZGGGCRRM-UHFFFAOYSA-N (4-methoxyphenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1=CC(OC)=CC=C1C(=O)N1CCN(C)CC1 DWPVVZZGGGCRRM-UHFFFAOYSA-N 0.000 description 1
CVZUKWBYQQYBTF-ZDUSSCGKSA-N (4s)-4-[(2-methylpropan-2-yl)oxycarbonylamino]-5-oxo-5-phenylmethoxypentanoic acid Chemical compound CC(C)(C)OC(=O)N[C@@H](CCC(O)=O)C(=O)OCC1=CC=CC=C1 CVZUKWBYQQYBTF-ZDUSSCGKSA-N 0.000 description 1
WZRKSPFYXUXINF-UHFFFAOYSA-N 1-(bromomethyl)-4-methylbenzene Chemical group CC1=CC=C(CBr)C=C1 WZRKSPFYXUXINF-UHFFFAOYSA-N 0.000 description 1
XKIIVWNSKUSCBZ-UHFFFAOYSA-N 1-methyl-2-nitrososulfanylpiperidine Chemical compound N(=O)SC1N(CCCC1)C XKIIVWNSKUSCBZ-UHFFFAOYSA-N 0.000 description 1
PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical compound CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
WXTMDXOMEHJXQO-UHFFFAOYSA-N 2,5-dihydroxybenzoic acid Chemical compound OC(=O)C1=CC(O)=CC=C1O WXTMDXOMEHJXQO-UHFFFAOYSA-N 0.000 description 1
NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
FDISORFXYQXQES-UHFFFAOYSA-N 2-amino-3-benzyl-3-[(4-methylphenyl)methylsulfanyl]-4-phenylbutanoic acid Chemical compound C1=CC(C)=CC=C1CSC(C(N)C(O)=O)(CC=1C=CC=CC=1)CC1=CC=CC=C1 FDISORFXYQXQES-UHFFFAOYSA-N 0.000 description 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
235000007173 Abies balsamea Nutrition 0.000 description 1
206010002383 Angina Pectoris Diseases 0.000 description 1
101150041968 CDC13 gene Proteins 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
208000024172 Cardiovascular disease Diseases 0.000 description 1
241000581364 Clinitrachus argentatus Species 0.000 description 1
102000008186 Collagen Human genes 0.000 description 1
108010035532 Collagen Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
244000018716 Impatiens biflora Species 0.000 description 1
ODUCDPQEXGNKDN-UHFFFAOYSA-N Nitrogen oxide(NO) Natural products O=N ODUCDPQEXGNKDN-UHFFFAOYSA-N 0.000 description 1
XOWVFANEOZMPKG-REOHCLBHSA-N S-nitroso-L-cysteine Chemical compound OC(=O)[C@@H](N)CSN=O XOWVFANEOZMPKG-REOHCLBHSA-N 0.000 description 1
239000005864 Sulphur Substances 0.000 description 1
DHXVGJBLRPWPCS-UHFFFAOYSA-N Tetrahydropyran Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 1
208000007536 Thrombosis Diseases 0.000 description 1
HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 1
208000035868 Vascular inflammations Diseases 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
VXDSLUMUNWTSDB-UHFFFAOYSA-N acetic acid;chloroform;methanol Chemical compound OC.CC(O)=O.ClC(Cl)Cl VXDSLUMUNWTSDB-UHFFFAOYSA-N 0.000 description 1
PBCJIPOGFJYBJE-UHFFFAOYSA-N acetonitrile;hydrate Chemical compound O.CC#N PBCJIPOGFJYBJE-UHFFFAOYSA-N 0.000 description 1
239000012346 acetyl chloride Substances 0.000 description 1
238000010306 acid treatment Methods 0.000 description 1
YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
239000013543 active substance Substances 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
238000013019 agitation Methods 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
238000004873 anchoring Methods 0.000 description 1
239000008346 aqueous phase Substances 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000002775 capsule Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
238000012512 characterization method Methods 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
229920001436 collagen Polymers 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
239000006071 cream Substances 0.000 description 1
DEZRYPDIMOWBDS-UHFFFAOYSA-N dcm dichloromethane Chemical compound ClCCl.ClCCl DEZRYPDIMOWBDS-UHFFFAOYSA-N 0.000 description 1
230000007423 decrease Effects 0.000 description 1
UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
ZGTMUACCHSMWAC-UHFFFAOYSA-N disodium;2-[2-[bis(carboxymethyl)amino]ethyl-(carboxymethyl)amino]acetic acid Chemical compound [Na+].[Na+].OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O ZGTMUACCHSMWAC-UHFFFAOYSA-N 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
235000003969 glutathione Nutrition 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
229910052943 magnesium sulfate Inorganic materials 0.000 description 1
235000019341 magnesium sulphate Nutrition 0.000 description 1
238000001819 mass spectrum Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
AYOOGWWGECJQPI-NSHDSACASA-N n-[(1s)-1-(5-fluoropyrimidin-2-yl)ethyl]-3-(3-propan-2-yloxy-1h-pyrazol-5-yl)imidazo[4,5-b]pyridin-5-amine Chemical compound N1C(OC(C)C)=CC(N2C3=NC(N[C@@H](C)C=4N=CC(F)=CN=4)=CC=C3N=C2)=N1 AYOOGWWGECJQPI-NSHDSACASA-N 0.000 description 1
238000006386 neutralization reaction Methods 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
229960002748 norepinephrine Drugs 0.000 description 1
SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
HDEOKHIQTDMWTQ-UHFFFAOYSA-N oxane-4-thiol Chemical compound SC1CCOCC1 HDEOKHIQTDMWTQ-UHFFFAOYSA-N 0.000 description 1
230000003647 oxidation Effects 0.000 description 1
238000007254 oxidation reaction Methods 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
QCNSVCYISFVZIY-UHFFFAOYSA-N phosphane;pyrrolidine Chemical compound P.C1CCNC1 QCNSVCYISFVZIY-UHFFFAOYSA-N 0.000 description 1
229920000136 polysorbate Polymers 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
150000003109 potassium Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
230000008569 process Effects 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
235000018102 proteins Nutrition 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
238000011002 quantification Methods 0.000 description 1
230000036647 reaction Effects 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000002040 relaxant effect Effects 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000010288 sodium nitrite Nutrition 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
239000007858 starting material Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
239000003826 tablet Substances 0.000 description 1
DLYUQMMRRRQYAE-UHFFFAOYSA-N tetraphosphorus decaoxide Chemical compound O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 1
WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
ICRHORQIUXBEPA-UHFFFAOYSA-N thionitrous acid Chemical group SN=O ICRHORQIUXBEPA-UHFFFAOYSA-N 0.000 description 1
230000000472 traumatic effect Effects 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C381/00—Compounds containing carbon and sulfur and having functional groups not covered by groups C07C301/00 - C07C337/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Animal Behavior & Ethology (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Cardiology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Heart & Thoracic Surgery (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Vascular Medicine (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyrane Compounds (AREA)
Hydrogenated Pyridines (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)

OA1200100195A 1999-01-27 2000-01-19 S-nitrosothiols as agents for the treatment of circulatory dysfunctions. OA11823A (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES009900159A ES2147162B1 (es)	1999-01-27	1999-01-27	"s-nitrosotioles como agentes para el tratamiento de disfunciones circulatorias".

Publications (1)

Publication Number	Publication Date
OA11823A true OA11823A (en)	2005-08-16

Family

ID=8307080

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA1200100195A OA11823A (en)	1999-01-27	2000-01-19	S-nitrosothiols as agents for the treatment of circulatory dysfunctions.

Country Status (37)

Country	Link
US (1)	US6800612B2 (is)
EP (1)	EP1157987B1 (is)
JP (1)	JP3795330B2 (is)
KR (1)	KR100671878B1 (is)
CN (1)	CN1166631C (is)
AP (1)	AP1439A (is)
AT (1)	ATE249428T1 (is)
AU (1)	AU764725B2 (is)
BG (1)	BG64983B1 (is)
BR (1)	BR0007395B1 (is)
CA (1)	CA2359027C (is)
CU (1)	CU23098A3 (is)
CZ (1)	CZ298871B6 (is)
DE (2)	DE60005154T2 (is)
DK (1)	DK1157987T3 (is)
EA (1)	EA003577B1 (is)
EE (1)	EE04524B1 (is)
ES (2)	ES2147162B1 (is)
GB (1)	GB2363604B (is)
GE (1)	GEP20043220B (is)
HK (1)	HK1043586A1 (is)
HR (1)	HRP20010562B1 (is)
HU (1)	HUP0105203A3 (is)
ID (1)	ID29777A (is)
IL (1)	IL144381A (is)
IS (1)	IS2153B (is)
MX (1)	MXPA01007570A (is)
NO (1)	NO326806B1 (is)
NZ (1)	NZ513162A (is)
OA (1)	OA11823A (is)
PL (1)	PL202372B1 (is)
PT (1)	PT1157987E (is)
RS (1)	RS50072B (is)
SI (1)	SI1157987T1 (is)
TR (1)	TR200102003T2 (is)
WO (1)	WO2000044714A1 (is)
ZA (1)	ZA200106182B (is)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2173044B1 (es) *	2001-03-13	2004-01-16	Lacer Sa	Derivados de glicina, n-(n-l-gamma-glutamil-3-(nitrosotio)-l-valil) y sus aplicaciones.
EP1673384A4 (en) *	2003-09-26	2007-02-07	Nitromed Inc	NITROSED GLUTAMINE ACID COMPOUNDS, COMPOSITIONS AND USE METHOD
EP1939179A1 (en) *	2006-12-28	2008-07-02	Lacer, S.A.	Stable S-nitrosothiols, method of synthesis and use
WO2009050527A1 (en)	2007-10-17	2009-04-23	Biotech Hungary Kutató És Fejlesztési Kft.	Pharmaceutical composition comprising s-nitrosoglutathione and polysaccharide

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US37839A (en) *		1863-03-03		Improved spoke-machine
GB1567561A (en)	1977-01-18	1980-05-14	Ucb Sa	Amino-spiro(oxa-(orthia)cycloalkane-penam) - carboxylic acids
GB2052497B (en)	1979-06-25	1983-06-29	Ucb Sa	6 - amino - spiro - (penam - 2,4' - piperidine) - 3 - carboxylic acid derivatives
DE3805965A1 (de)	1988-02-25	1989-09-07	Tamas Geb Szenasi Eszter	Verwendung der pflanze euphorbia hirta l. und ihrer extrakte sowie ihrer wirkstoffe
US5025001A (en)	1988-06-15	1991-06-18	Brigham And Women's Hospital	S-nitroso derivatives of ACE inhibitors and the use thereof
DE69008454T2 (de) *	1989-08-07	1994-08-25	Takeda Chemical Industries Ltd	Nitrolsothiolderivate, ihre Herstellung und Verwendung.
ES2095317T3 (es)	1990-04-26	1997-02-16	Senju Pharma Co	Inhibidor de enfermedades hepaticas.
US5187305A (en) *	1990-11-26	1993-02-16	Glaxo Inc.	S-nitroso-N-alkonoylpenicillamines
AU3071592A (en)	1991-11-14	1993-06-15	Brigham And Women's Hospital	Nitrosylation of protein sh groups and amino acid residues as a therapeutic modality
IL106600A (en)	1992-08-07	1997-09-30	Sankyo Co	Peptides, pharmaceutical compositions containing the same and processes for the preparation thereof
DE69433478T2 (de) *	1993-09-17	2004-11-25	Brigham And Women's Hospital, Boston	Verwendung von stickoxid-addukten zur verhütung von thrombosen auf artifiziellen und vaskulären oberflächen
US5728705A (en)	1993-10-04	1998-03-17	The Trustees Of Columbia University In The City Of New York	Method of inducing vasorelaxation to treat pulmonary hypertension
ATE192922T1 (de)	1993-11-02	2000-06-15	Us Health	Verwendung von stickstoffoxid freisetzenden verbindungen zur herstellung eines arzneimittels zum schutz gegen die ischämischen reperfusionsschäden
GB9423868D0 (en)	1994-11-25	1995-01-11	Wellcome Found	Compounds for use in medicine
US6627738B2 (en)	1995-09-15	2003-09-30	Duke University	No-modified hemoglobins and uses therefor
AU6782198A (en)	1997-03-27	1998-10-20	Trustees Of Boston University	Novel antiplatelet agent

1999
- 1999-01-27 ES ES009900159A patent/ES2147162B1/es not_active Expired - Fee Related
2000
- 2000-01-19 WO PCT/ES2000/000019 patent/WO2000044714A1/es not_active Ceased
- 2000-01-19 CN CNB008030847A patent/CN1166631C/zh not_active Expired - Fee Related
- 2000-01-19 EA EA200100823A patent/EA003577B1/ru not_active IP Right Cessation
- 2000-01-19 AU AU30460/00A patent/AU764725B2/en not_active Ceased
- 2000-01-19 EE EEP200100389A patent/EE04524B1/xx not_active IP Right Cessation
- 2000-01-19 DE DE60005154T patent/DE60005154T2/de not_active Expired - Lifetime
- 2000-01-19 EP EP00900518A patent/EP1157987B1/en not_active Expired - Lifetime
- 2000-01-19 CZ CZ20012678A patent/CZ298871B6/cs not_active IP Right Cessation
- 2000-01-19 SI SI200030236T patent/SI1157987T1/xx unknown
- 2000-01-19 HK HK02103982.2A patent/HK1043586A1/en unknown
- 2000-01-19 DE DE10083902T patent/DE10083902T1/de not_active Ceased
- 2000-01-19 GE GEAP20006075A patent/GEP20043220B/en unknown
- 2000-01-19 RS YUP-536/01A patent/RS50072B/sr unknown
- 2000-01-19 HU HU0105203A patent/HUP0105203A3/hu unknown
- 2000-01-19 NZ NZ513162A patent/NZ513162A/xx not_active IP Right Cessation
- 2000-01-19 PT PT00900518T patent/PT1157987E/pt unknown
- 2000-01-19 OA OA1200100195A patent/OA11823A/en unknown
- 2000-01-19 GB GB0120581A patent/GB2363604B/en not_active Expired - Fee Related
- 2000-01-19 MX MXPA01007570A patent/MXPA01007570A/es not_active IP Right Cessation
- 2000-01-19 AP APAP/P/2001/002247A patent/AP1439A/en active
- 2000-01-19 AT AT00900518T patent/ATE249428T1/de not_active IP Right Cessation
- 2000-01-19 HR HR20010562A patent/HRP20010562B1/xx not_active IP Right Cessation
- 2000-01-19 KR KR1020017009522A patent/KR100671878B1/ko not_active Expired - Fee Related
- 2000-01-19 ES ES00900518T patent/ES2206178T3/es not_active Expired - Lifetime
- 2000-01-19 DK DK00900518T patent/DK1157987T3/da active
- 2000-01-19 IL IL14438100A patent/IL144381A/xx not_active IP Right Cessation
- 2000-01-19 TR TR2001/02003T patent/TR200102003T2/xx unknown
- 2000-01-19 CA CA002359027A patent/CA2359027C/en not_active Expired - Fee Related
- 2000-01-19 JP JP2000595971A patent/JP3795330B2/ja not_active Expired - Fee Related
- 2000-01-19 ID IDW00200101662A patent/ID29777A/id unknown
- 2000-01-19 BR BRPI0007395-4A patent/BR0007395B1/pt not_active IP Right Cessation
- 2000-01-19 PL PL349006A patent/PL202372B1/pl not_active IP Right Cessation
2001
- 2001-07-06 NO NO20013385A patent/NO326806B1/no not_active IP Right Cessation
- 2001-07-23 IS IS6020A patent/IS2153B/is unknown
- 2001-07-24 US US09/912,164 patent/US6800612B2/en not_active Expired - Fee Related
- 2001-07-26 ZA ZA200106182A patent/ZA200106182B/en unknown
- 2001-07-30 CU CU20010181A patent/CU23098A3/es not_active IP Right Cessation
- 2001-08-16 BG BG105824A patent/BG64983B1/bg unknown

Also Published As

Publication number	Publication date
GB2363604B (en)	2003-09-10
IL144381A (en)	2005-08-31
DE10083902T1 (de)	2002-01-10
CZ298871B6 (cs)	2008-02-27
BG105824A (en)	2002-06-28
CU23098A3 (es)	2005-11-18
BG64983B1 (bg)	2006-11-30
NZ513162A (en)	2003-01-31
ES2206178T3 (es)	2004-05-16
KR20010101767A (ko)	2001-11-14
NO20013385D0 (no)	2001-07-06
YU53601A (sh)	2004-03-12
CN1337946A (zh)	2002-02-27
NO326806B1 (no)	2009-02-16
CZ20012678A3 (cs)	2001-10-17
AU764725B2 (en)	2003-08-28
DK1157987T3 (da)	2003-11-24
JP2002535385A (ja)	2002-10-22
GB0120581D0 (en)	2001-10-17
BR0007395B1 (pt)	2010-11-16
SI1157987T1 (en)	2004-02-29
EA200100823A1 (ru)	2002-02-28
EP1157987B1 (en)	2003-09-10
HRP20010562B1 (en)	2010-08-31
ES2147162B1 (es)	2001-03-16
ZA200106182B (en)	2002-10-28
HUP0105203A3 (en)	2002-08-28
KR100671878B1 (ko)	2007-01-19
AP1439A (en)	2005-06-27
AU3046000A (en)	2000-08-18
HRP20010562A2 (en)	2002-08-31
CN1166631C (zh)	2004-09-15
GEP20043220B (en)	2004-04-26
ES2147162A1 (es)	2000-08-16
US6800612B2 (en)	2004-10-05
GB2363604A (en)	2002-01-02
PL202372B1 (pl)	2009-06-30
EE200100389A (et)	2002-12-16
EP1157987A1 (en)	2001-11-28
IS6020A (is)	2001-07-23
WO2000044714A1 (es)	2000-08-03
CA2359027C (en)	2008-10-28
ID29777A (id)	2001-10-11
PT1157987E (pt)	2004-01-30
AP2001002247A0 (en)	2001-09-30
HUP0105203A2 (en)	2002-06-29
US20020058629A1 (en)	2002-05-16
CA2359027A1 (en)	2000-08-03
PL349006A1 (en)	2002-06-17
IS2153B (is)	2006-10-13
HK1043586A1 (en)	2002-09-20
DE60005154T2 (de)	2004-07-08
JP3795330B2 (ja)	2006-07-12
MXPA01007570A (es)	2003-05-14
EA003577B1 (ru)	2003-06-26
IL144381A0 (en)	2002-05-23
RS50072B (sr)	2009-01-22
EE04524B1 (et)	2005-08-15
NO20013385L (no)	2001-09-17
BR0007395A (pt)	2001-10-30
ATE249428T1 (de)	2003-09-15
DE60005154D1 (de)	2003-10-16
TR200102003T2 (tr)	2001-12-21

Publication	Publication Date	Title
JP7368637B2 (ja)	2023-10-24	線維芽細胞活性化タンパク質を阻害するための化合物
ES2258318T3 (es)	2006-08-16	Derivados de amida ciclica que inhiben la catepsina k.
CA1312702C (en)	1993-01-12	Oligopeptidyl nitrile derivatives, agents containing them, a process for their preparation, and their use
JPS6059226B2 (ja)	1985-12-24	プロリン誘導体および関連化合物
US7038074B2 (en)	2006-05-02	Arginine mimetics as factor Xa inhibitors
CN114591201B (zh)	2024-06-25	具有HDACi药效团的β-榄香烯衍生物及其制备方法和应用
US5883121A (en)	1999-03-16	Epoxysuccinamide derivative or salt thereof, and medicine comprising the same
PT98227A (pt)	1992-05-29	Processo de preparacao de 1,4-diamino-2-3-di-hidroxi-butanos substituidos e de composicoes farmaceuticas que os contem
OA11823A (en)	2005-08-16	S-nitrosothiols as agents for the treatment of circulatory dysfunctions.
RU2017748C1 (ru)	1994-08-15	Производные нитратоалкановых кислот или их фармацевтически приемлемые соли
US20200071360A1 (en)	2020-03-05	Tailored cyclodepsipeptides as potent non-covalent serine protease inhibitors
US10556878B2 (en)	2020-02-11	Thiourea compounds and their use as inhibitors of Sirt2 or Sirt5
CA3166572C (en)	2025-08-12	Compounds for inhibition of fibroblast activation protein
AU611269B2 (en)	1991-06-06	Peptides with pharmaceutical activity
EP4276097A1 (en)	2023-11-15	Aminopyrimidinyl derivatives for the treament of parkinson's disease
RU2689381C1 (ru)	2019-05-28	Хиральные S-монотерпенилцистеины
KR20260057452A (ko)	2026-04-28	화합물 및 용도
KR20190043031A (ko)	2019-04-25	아마톡신 유도체 및 이의 제조방법